Sun Pharma to acquire Organon for $11.75 billion in all-cash deal
read at Endpoints ↗DealPositive
Indian pharmaceutical company Sun Pharma announced it will purchase Organon, a company focused on women's health and biosimilars that was spun out of Merck in 2021.
The transaction is an all-cash deal valued at about $11.75 billion, pricing Organon's shares at $14 each.
The acquisition expands Sun Pharma's portfolio into new therapeutic areas and strengthens its presence in the global market.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Sun Pharma to buy Organon for $11.75B in major portfolio expansion”
read at Endpoints ↗97 words · retrieved Apr 27
comments(0)
5-min edit window · permanent after that